What: Shares in biotechnology hopeful Unilife Corporation (ASX: UNS) tumbled around 35% to 24 cents today after the steam came out of yesterday’s big price rise on positive news of a new commercial agreement with a US biotech partner.

So what: Dual listed on the ASX and Nasdaq, Unilife is a US-based company that designs, manufactures and supplies injectable drug delivery systems for use by healthcare professionals or commercial pharmaceutical or biotechnology partners.

Overnight the Nasdaq listed scrip climbed 31.3% and today’s price action on the ASX is likely the result of investors adjusting to the valuation US investors placed on the business in the wake of the news over the commercial agreement.

The commercial agreement will see Unilife receive a US$15 million non-refundable payment from large US biotechnology business Amgen, with plenty of further opportunity for Unilife to supply its injector devices to Amgen for use in the global healthcare markets it operates in.

Now what: The fact that there appears to be demand for Unilife’s injectable devices from a large healthcare business is a positive sign. However, the shares have been on a wild ride over the last year losing around 70% of their value since February 2015 despite the recent strong price rises and investors should expect the stock to remain volatile.

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.


Forget BHP and Woolworths. This "dirt cheap" company is growing like gangbusters, and trading on a 5.6% dividend yield, FULLY FRANKED (8% gross). With interest rates set to stay at these low levels for years to come, for hungry investors, including SMSFs, this ASX company could be the "holy grail" of dividend plays for 2016.

Enter your email below to discover the name, code and a full investment analysis in our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2016.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tom Richardson has no position in any stocks mentioned.

You can find Tom on Twitter @tommyr345

Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.